GRAL GRAIL, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1699031 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY0.0%
TTM EPS YoY13.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-347.3%
Net margin-243.8%
FCF margin-187.3%
EBITDA margin-337.4%
Returns
ROE-17.3%
ROA-15.2%
ROIC (approx.)-20.1%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio8.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37.53M | $44.69M | $40.78M | $43.60M | $36.19M | $35.54M | $31.84M | $38.25M |
| R&D expense | $44.07M | $47.43M | $48.02M | $46.90M | $48.65M | $46.63M | $53.62M | $48.33M |
| SG&A expense | $40.74M | $50.71M | $42.77M | $38.71M | $37.41M | $37.91M | $45.07M | $42.12M |
| Operating income | -$144.62M | -$173.78M | -$135.76M | -$124.41M | -$125.29M | -$158.85M | -$153.61M | -$136.94M |
| Pretax income | -$137.32M | -$166.71M | -$127.52M | -$116.52M | -$118.72M | -$152.86M | -$146.41M | -$126.99M |
| Income tax | -$33.75M | -$56.46M | -$34.34M | -$17.34M | -$29.74M | -$38.87M | -$40.20M | -$29.93M |
| Net income | -$103.57M | -$110.25M | -$93.19M | -$99.18M | -$88.98M | -$113.98M | -$106.21M | -$97.07M |
| EBITDA | -$140.73M | -$169.68M | -$131.56M | -$120.09M | -$120.89M | -$154.26M | -$148.91M | -$132.08M |
| EPS (basic) | -2.21 | -2.56 | -2.29 | — | -2.46 | -3.18 | -3.10 | — |
| EPS (diluted) | -2.21 | -2.56 | -2.29 | — | -2.46 | -3.18 | -3.10 | — |
| Weighted avg. shares (diluted) | 46.78M | 43.11M | 40.64M | — | 36.12M | 35.79M | 34.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.98M | $55.65M | $69.34M | $249.73M | $126.89M | $127.43M | $133.90M | $217.58M |
| Receivables | $19.00M | $19.76M | $20.34M | $18.30M | $16.28M | $16.31M | $19.31M | $20.31M |
| Current assets | $842.80M | $914.72M | $877.35M | $953.85M | $589.38M | $651.84M | $727.65M | $819.86M |
| PP&E, net | $42.69M | $44.34M | $47.85M | $51.81M | $56.18M | $60.21M | $64.61M | $69.06M |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Intangibles | $1.75B | $1.78B | $1.82B | $1.85B | $1.89B | $1.92B | $1.98B | $2.02B |
| Total assets | $2.73B | $2.84B | $2.80B | $2.92B | $2.60B | $2.70B | $2.85B | $2.98B |
| Current liabilities | $94.33M | $83.54M | $74.71M | $79.67M | $77.43M | $70.64M | $74.98M | $76.92M |
| Total liabilities | $277.04M | $301.03M | $302.79M | $344.15M | $361.07M | $387.91M | $433.94M | $479.90M |
| Shareholders' equity | $2.45B | $2.54B | $2.50B | $2.58B | $2.24B | $2.31B | $2.41B | $2.50B |
| Shares outstanding | 44.75M | 44.67M | 41.13M | 40.33M | 36.16M | 36.05M | 35.30M | 33.89M |
| Cash flow statement | ||||||||
| Operating cash flow | -$74.74M | -$80.73M | -$86.99M | -$63.78M | -$63.24M | -$76.97M | -$95.01M | -$93.49M |
| Capital expenditure | $4.73M | $432,000 | $503,000 | $94,000 | $384,000 | $369,000 | $62,000 | $303,000 |
| Free cash flow | -$79.47M | -$81.16M | -$87.49M | -$63.88M | -$63.63M | -$77.33M | -$95.07M | -$93.79M |
| Investing cash flow | $47.68M | -$46.58M | -$93.44M | -$236.70M | $66.67M | $70.37M | $14.61M | -$546.11M |
| Financing cash flow | $370,000 | — | — | $423.32M | $0 | $0 | $0 | $0 |
| Depreciation & amortization | $3.89M | $4.11M | $4.21M | $4.32M | $4.40M | $4.59M | $4.70M | $4.86M |
| Stock-based compensation | $14.11M | $19.56M | $16.79M | $13.77M | $14.14M | $14.17M | $16.21M | $13.58M |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.